Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function

Medical and Pediatric Oncology

Volumn 40, Issue 6, 2003, Pages 348-354

  Hempel, Lutz ^a   Misselwitz, Joachim ^a   Fleck, Christian ^a   Kentouche, Karim ^a   Leder, Christiane ^a   Appenroth, Dorothea ^a   Rost, Michael ^a   Zintl, Felix ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Childhood cancer; High dose methotrexate; Nephrotoxicity; Renal function

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; DISEASE COURSE; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEINURIA;

ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY TUBULES; MALE; METHOTREXATE; PROSPECTIVE STUDIES; PROTEINURIA;

EID: 0242500775     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10293     Document Type: Article

References (27)

1. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948;238:787-793.
2. Djerassi I, Rominger CJ, Kim JS. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer. Cancer 1972;30:22-29.
3. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30:1627-1631.
4. Bleyer WA. The clinical pharmacology of methotrexate: New applications of an old drug. Cancer 1978;41:36-51.
5. Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983;1:208-216.
6. Lawrenz-Wolf B, Wolfrom C, Frickel C, et al. Severe renal impairment of methotrexate elimination after high-dose therapy. Klin Pädiatr 1994;206:319-326.
7. Maiche AG. Renal insufficiency in patients treated with high dose methotrexate. Acta Oncol 1988;27:73-74.
8. Sasaki K, Tanaka J, Fujimoto T. Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol 1984;13:9-13.
9. Smeland E, Fuskevag OM, Nymann K, et al. High-dose 7-hydromethotrexate: Acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol 1996;37:415-422.
10. Christensen ML, Rivera GK, Crom WR, et al. Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia. J Clin Oncol 1988;6:797-801.
11. Perazella MA. Crystal-induced acute renal failure. Am J Med 1999;106:459-465.
12. Kovacs GT, Paal C, Somlo P, et al. Proteinuria due to suboptimal hydration with high-dose methotrexate therapy. Cancer Chemother Pharmacol 1993;33:262-263.
13. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994;12:1667-1672.
14. Bertino JR. Clinical pharmacology of methotrexate. Med Pediatr Oncol 1982;10:401-411.
15. Fuskevag OM, Kristiansen C, Olsen R, et al. Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate. Ultrastruct Pathol 2000;24:325-332.
16. Deray G, Khayat D, Cacoub P, et al. The effects of diltiazem on methotrexate-induced nephrotoxicity. Eur J Clin Pharmacol 1989;37:337-340.
17. Erttmann R, Bielack S, Landbeck G. Kinetics of 7-hydroxymethotrexate after high-dose methotrexate therapy. Cancer Chemother Pharmacol 1985;15:101-104.
18. Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992;1(38, Suppl.):14-19.
19. Itoh Y, Kawai T. Human alpha-1-microglobulin: Its measurement and clinical significance. Clin Lab Analysis 1990;4:376-384.
20. Weber MH, Verwiebe R. Alpha 1-microglobulin (protein HC): Features of a promising indicator of proximal tubular dysfunction. Eur J Clin Chem Clin Biochem 1992;30:683-691.
21. Schwartz GJ, Haycock GB, Edelmann CM, Jr. A simple estimation of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-263.
22. Nürnberg B, Kohlbrenner M, Faulkner R, et al. Rapid quantitation of methotrexate and its metabolites in human serum, urine and bile, using solid-phase extraction and high-performance liquid chromatography. J Chromatogr 1989;24:476-482.
23. Seidel H, Moe PJ, Nygaard R, et al. Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. Pediatr Hematol Oncol 1994;11:165-172.
24. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986;314:471-477.
25. Goren MP, Wright RK, Horowitz ME, et al. Urinary N-Acetyl-β-D-Glucosaminidase and serum creatinine concentrations predict impaired excretion of methotrexate. J Clin Oncol 1997;5:804-810.
26. Patzer L, Hempel L, Misselwitz J, et al. Renal function after conditioning therapy for bone marrow transplantation in childhood. Med Pediatr Oncol 1997;28:274-283.
27. Keefe DA, Capizzi RL, Rudnick SA. Methotrexate cytotoxicity for L5178Y/Asn-Lymphoblasts: Relationship of dose and duration of exposure to tumor cell viability. Cancer Res 1982;42:1641-1645.